Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 02 September, 2011

AstraZeneca PLC

Top-Line Results from SATURN study

RNS Number : 5096N
AstraZeneca PLC
02 September 2011
 



AstraZeneca Announces Top-Line Results From SATURN Study

 

AstraZeneca today announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN).  SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.

 

The results for the primary efficacy measure, which was change from baseline in percent atheroma volume (PAV) in a ≥40 mm segment of the targeted coronary artery as assessed by intravascular ultrasound (IVUS), demonstrated a numerically greater reduction in favour of CRESTOR versus atorvastatin but did not reach statistical significance.

 

For the secondary IVUS measure, which was change from baseline in total atheroma volume (TAV) within the targeted coronary artery, CRESTOR demonstrated a statistically significant reduction compared with atorvastatin.

 

Tolerability and efficacy of CRESTOR seen in SATURN were in line with previous studies and approved product labelling.

 

Further data and analyses will be presented by the study's academic investigators at the American Heart Association Scientific Sessions (AHA) on Tuesday, 15 November.

 

About SATURN

SATURN is a 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study of approximately 1,300 patients, investigating the effects of treatment with rosuvastatin 40 mg and atorvastatin 80 mg on atherosclerotic disease burden as measured by IVUS in patients with coronary artery disease. 

 

About PAV and TAV

Percent atheroma volume (PAV) and total atheroma volume (TAV) can be estimated as part of an intravascular ultrasound examination of a coronary artery. PAV and TAV are two different derivatives of the same measurements taken with a tiny ultrasound probe that is inserted inside the coronary artery.  In effect, they take the same ultrasound data, but look at the volume of plaques, or fatty deposits, in different ways to represent what is happening in the patient's artery.

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 




Media Enquiries UK

 

Esra Erkal-Paler

+44 207 604 8030 (24 hours


Abigail Baron

+44 20 7604 8034 (24 hours)





Investor Enquiries UK



Jonathan Hunt

+44 20 7604 8122

mob: +44 7775 704032

Karl Hård

+44 20 7604 8123

mob: +44 7789 654364

Nicklas Westerholm

 

+44 20 7604 8124

mob: +44 7585 404950

Investor Enquiries US



Ed Seage

+1 302 886 4065

mob: +1 302 373 1361

Jorgen Winroth

+1 212 579 0506

mob: +1 917 612 4043

 

 

2 September 2011

- ENDS -


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEASNAEDAFEEF

a d v e r t i s e m e n t